Burcon Nutrascience (BU) AI Stock Analysis

• Market Cap: C$31.22M
• Dividend Yield: N/A
• Average Volume (3M): 6.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: 190.07%
• EPS Growth: -2.88%
• Country: CA
• Employees: 25
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): -0.28
• Shares Outstanding: 12,692,276
• 10 Day Avg. Volume: 9,144
• 30 Day Avg. Volume: 6,578
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.14
• Price to Sales (P/S): 38.96
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.07
• Revenue Forecast (FY): C$3.20M

• Rating: 47 Neutral
• Price Target: C$2.50 ▲(44.51% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held down primarily by weak financial fundamentals: persistent losses, ongoing cash burn, and a deteriorated balance sheet with negative equity. Technical signals are moderately supportive, but valuation remains challenging due to negative earnings and no dividend yield data.

Positive Factors

Strong recent revenue momentum

Sustained double-digit TTM revenue growth indicates product adoption and early commercial traction. Over 2-6 months this momentum supports scaling conversations with partners, improves prospects for licensing/royalty realization, and validates underlying technology demand.

IP-driven, capital-light business model

A licensing and IP-centric model enables capital-light expansion via partner manufacturing and royalties. Structurally this reduces long-term capex needs, allows faster market reach through established partners, and can create recurring revenue if partners commercialize at scale.

Diversified plant-protein technology exposure

Technology applicable to multiple plant sources broadens addressable markets and lowers reliance on one crop. Structurally this boosts resilience to raw-material shifts and aligns with secular growth in plant-based foods, improving long-term partner interest across categories.

Negative Factors

Persistent unprofitable operations

Negative gross profit and sustained net losses indicate the business has not yet achieved a sustainable cost structure. Over a multi-month horizon this limits reinvestment capacity, undermines credibility in partner negotiations, and delays self-funded scale.

Ongoing negative cash generation

Continual negative operating and free cash flow forces reliance on external financing or partner milestones. Structurally this raises dilution and refinancing risk, constrains long-term R&D or commercialization spending, and can slow execution of strategic partnerships.

Deteriorated balance sheet and high leverage

Negative equity and elevated leverage materially reduce financial flexibility and increase insolvency risk. Over months this limits ability to absorb shocks, raises funding costs, and can deter large-scale partners or customers concerned about supplier continuity.

Burcon Nutrascience Business Overview & Revenue Model

Company Description

Burcon NutraScience Corporation, together with its subsidiaries, develops plant proteins and ingredients for use in the food and beverage industries in Canada. The company's products include Peazazz, a pea protein for use in dairy alternatives, ready-to-drink beverages, dry blended beverages, bars, baked goods, and meat substitute products; and Peazac and Peazac 850, a pea protein for plant-based meat alternative products, ready-to-mix powders, ready-to-mix beverages, dairy alternatives, and nutrition bars, as well as other applications requiring the most neutral flavor and moderate viscosity. It provides Puratein, a canola protein isolate for use in meat alternatives, such as burgers, sausages, and nutrition bars; Supertein, a canola protein that is a light-colored powder for use in non-dairy frozen desserts, egg alternative, plant-based marshmallows and ready-to-mix beverages, whipped toppings, and plant-based bars; and Nutratein, a canola protein comprising a mixture of globulin and albumin proteins for use in meat and egg alternatives, and other plant-based functional foods. In addition, the company offers Nutratein-PS and Nutratein-TZ, a blend of Peazac pea protein; and CLARISOY, a soy protein for use in sports nutrition beverages, citrus-based drinks, fruit-flavored beverages, lemonades, powdered beverage mixes, and other foods and nutritional products. Further, it provides MeritPro, a nutritional protein blend, including allergen-free, gluten-free, non-dairy, non-GMO, and vegan. The company was formerly known as Burcon Capital Corp. and changed its name to Burcon NutraScience Corporation in October 1999. The company was incorporated in 1998 and is headquartered in Vancouver, Canada.

How the Company Makes Money

Burcon Nutrascience generates revenue through several key streams, including the licensing of its proprietary protein extraction and purification technologies to food manufacturers, which allows them to produce their own plant-based protein products. Additionally, the company sells its protein ingredients directly to food and beverage companies for inclusion in their products. Significant partnerships with major food industry players enhance Burcon's market reach and credibility, contributing to its earnings. The company also explores joint ventures and collaborations that leverage its technology and product offerings in the rapidly expanding plant-based market, providing further avenues for revenue generation.

Burcon Nutrascience Financial Statement Overview

Summary

Despite sharp TTM revenue growth (+84.31%), profitability and cash generation are very weak (negative gross profit, large losses, and consistently negative operating/free cash flow). Balance sheet risk is elevated with negative equity and high leverage, limiting financial flexibility.

Income Statement

TTM (Trailing-Twelve-Months) revenue improved sharply (+84.31%), but profitability is very weak: gross profit is negative and losses remain large (net margin about -13.8%). Across recent annual periods, revenue is small and volatile while operating losses persist, indicating the company has not yet reached a sustainable cost structure despite top-line momentum.

Balance Sheet

The balance sheet shows elevated financial risk in the latest TTM (Trailing-Twelve-Months) period: equity is negative, while total debt is high, driving an extremely high debt-to-equity figure. Earlier annual reports showed positive equity and more moderate leverage, but the shift to negative equity suggests meaningful balance sheet deterioration and limited financial flexibility.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow negative in the TTM (Trailing-Twelve-Months) period and also negative in each annual period shown, implying ongoing cash burn. A partial positive is that free cash flow loss did not worsen dramatically versus net loss (free cash flow to net income > 1), but the business still appears dependent on external funding to sustain operations.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.48M	381.40K	184.36K	363.91K	171.47K	258.65K
Gross Profit	-6.68M	-870.76K	184.36K	363.91K	171.47K	-527.31K
EBITDA	-8.32M	-7.43M	-6.23M	-18.90M	-9.92M	-4.73M
Net Income	-12.90M	-8.26M	-7.45M	-25.36M	-10.26M	-617.49K
Balance Sheet
Total Assets	23.97M	30.66M	12.91M	9.90M	29.35M	37.72M
Cash, Cash Equivalents and Short-Term Investments	1.29M	7.28M	4.20M	1.46M	7.00M	13.97M
Total Debt	37.65M	22.40M	6.67M	5.17M	73.14K	33.70K
Total Liabilities	26.46M	23.71M	7.76M	5.76M	1.10M	1.45M
Stockholders Equity	-2.49M	6.94M	5.15M	4.14M	28.25M	36.27M
Cash Flow
Free Cash Flow	-8.15M	-5.82M	-5.90M	-6.38M	-7.18M	-5.91M
Operating Cash Flow	-7.27M	-5.51M	-5.78M	-6.02M	-5.91M	-3.03M
Investing Cash Flow	-2.25M	-1.66M	-39.49K	-4.43M	-1.23M	-2.72M
Financing Cash Flow	10.36M	10.23M	8.56M	4.90M	174.08K	4.70M

Burcon Nutrascience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.73
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BU, the sentiment is Positive. The current price of 1.73 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 1.88, and below the 200-day MA of 2.30, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 72.60 is Negative, neither overbought nor oversold. The STOCH value of 82.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BU.

Burcon Nutrascience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
BU	47 Neutral	C$31.22M	-2.30	-1208.82%	―	190.07%	-2.88%
BABY	44 Neutral	C$2.99M	-0.21	-517.87%	―	-25.08%	65.57%
CULT	42 Neutral	C$587.13K	-0.07	-190.55%	―	―	-126.28%
NPRA	41 Neutral	C$11.38M	-5.15	―	―	69.12%	43.02%
PNGA	27 Underperform	C$8.98M	-2.33	-86.40%	―	-49.04%	15.66%

Burcon Nutrascience Corporate Events

Burcon Raises $4 Million Cash in Convertible Debenture Financing to Fund Scale-Up

Burcon NutraScience has closed the second tranche of its non-brokered private placement of convertible debentures, issuing $2.75 million in debentures and bringing total cash raised from the first two tranches to $4 million toward an aggregate $6.9 million financing. With the cash component of the financing now secured and a final non-cash loan-conversion tranche expected by late April, the company says it has strengthened its balance sheet to support scaling production and accelerating commercial execution, while insider participation and loan offsets structure the deal as a related-party transaction under Canadian securities rules.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon Shareholders Clear Path for Convertible Debenture Financing

Burcon NutraScience said shareholders approved all matters at its February 20, 2026 special meeting, including resolutions tied to a private placement of convertible debentures and an extension to the expiry date of outstanding insider-held warrants. With these approvals in place, the company expects to close the convertible debenture financing around February 24, 2026, strengthening its capital position to support ongoing operations and its role as a key player in the competitive plant-based protein sector.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon’s Revenue Surges as Plant-Protein Demand Accelerates Amid Ongoing Losses

Burcon NutraScience reported fiscal 2026 third-quarter revenue of $739,000, an increase of about 1,100% from a year earlier, as commercial production ramped up and recurring customer orders grew. Management said demand for its plant-based protein ingredients is outpacing expectations, with more than 200 active customer projects and clients moving from trials to larger repeat purchases.

To support this growth, Burcon is investing in expanded production capacity and operational capabilities, underpinned by a $6.9 million private placement of convertible debentures led by its manufacturing partner. Despite the revenue surge, the company posted a nine-month net loss of $10.7 million and negative working capital of $9.7 million, reflecting higher startup and production costs at its Galesburg facility even as it reduces research, development, and administrative spending to focus on commercialization.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon Seeks Warrant Extension to Fund Plant-Protein Capacity Expansion

Burcon NutraScience has called a special virtual shareholders’ meeting for February 20, 2026, as it moves to extend the expiry of 1.54 million outstanding warrants to June 30, 2027, a step the company says is intended to encourage warrant exercises and generate cash to support capacity expansion without resorting to additional, more costly financings. The expiry dates on warrants held by non-insiders will be formally extended effective February 19, 2026, while similar extensions for tranches held by insiders require and will be put to a disinterested shareholder vote at the meeting, with the outcome determining whether those insider-held warrants are amended or left unchanged; the move underscores Burcon’s effort to shore up its balance sheet and fund growth at a time when its share price and near-term warrant expiries could otherwise limit its access to this source of capital.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon Sets Feb. 11 Call as Growing Demand Drives Scale-Up in Plant-Based Proteins

Burcon NutraScience will hold an investor conference call and webcast on February 11, 2026, to review its fiscal 2026 third-quarter results for the period ended December 31, 2025, with the financial figures to be released earlier that day. Management highlighted that customer demand is surpassing expectations, with commercial orders converting into recurring revenue and production now serving multiple customers, prompting the company to scale operations in a bid to drive sustained revenue growth and reinforce its position in the competitive plant-based protein sector.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon Upsizes Convertible Debenture Financing to $6.9 Million Amid Strong Insider Support

Burcon NutraScience has upsized its non-brokered private placement of convertible debentures to an aggregate principal amount of up to $6.9 million, citing strong investor demand despite challenging market conditions. Insiders and the company’s manufacturing partner owners have committed to subscribe for at least $5 million of the offering, which has received conditional approval from the Toronto Stock Exchange and is expected to support accelerated production and sales efforts as Burcon pursues a revenue target of more than $10 million in 2026.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon Raises Initial $1.25 Million in Insider-Backed Convertible Debenture Financing

Burcon NutraScience has closed the first tranche of a non-brokered private placement of unsecured convertible debentures, raising $1.25 million from its manufacturing partner owners as part of a financing of up to $6.3 million that has conditional approval from the Toronto Stock Exchange. Insiders and the company’s manufacturing partner owners have committed to invest at least $5 million, with a second and final tranche expected to close after disinterested shareholder approval at a special meeting in February 2026; the debentures carry 15% annual interest, a four-year term, and are convertible into common shares or pre-funded warrants at $1.60, a structure that strengthens Burcon’s balance sheet to support scaling production and ingredient sales while potentially increasing insider ownership above 20%.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.

Burcon NutraScience Reports Strong Growth and Momentum Heading into 2026

Burcon NutraScience has reported a strong year of execution and commercial momentum, with significant achievements in commercial execution, manufacturing, and technology validation positioning the company for substantial growth in 2026. The company has seen customers transition from evaluation to commercial purchase orders, driven by the differentiation of its high-purity, clean-tasting protein products. Burcon’s strategic partnership with RE ProMan LLC has enabled scalable production to meet growing demand, and the successful validation of its patented protein technologies at full commercial scale reduces technology and execution risk. The company is making targeted production investments and finalizing a financing to support accelerated growth and achieve positive cash flow, with a revenue target of over $10 million for 2026.

The most recent analyst rating on (TSE:BU) stock is a Hold with a C$1.50 price target. To see the full list of analyst forecasts on Burcon Nutrascience stock, see the TSE:BU Stock Forecast page.